Details of the Drug Combination

General Information of Drug Combination (ID: DCFTQT6)

Drug Combination Name
Gadobenate Dimeglumine Gadodiamide
Indication
Disease Entry Status REF
Motor Function Phase 4 [1]
Component Drugs Gadobenate Dimeglumine   DM4VAOG Gadodiamide   DMXPBAR
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Gadobenate Dimeglumine
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [2]
Gadobenate Dimeglumine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serum albumin (ALB) TTFNGC9 ALBU_HUMAN Binder [4]
------------------------------------------------------------------------------------
Gadobenate Dimeglumine Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [5]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [5]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [5]
------------------------------------------------------------------------------------
Indication(s) of Gadodiamide
Disease Entry ICD 11 Status REF
Central nervous system disease 8A04-8D87 Approved [3]

References

1 ClinicalTrials.gov (NCT04373564) Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
2 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
5 Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.